Please login to the form below

Pharma Market Research Report - Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016
2016 will continue to see an increase in the number of requests for research projects investigating the market opportunity for rare disease and orphan drugs. Last year the FDA approved 48 drugs in rare diseases, including both novel and repurposed drugs.

Rare diseases are attractive to pharma for a number of reasons. Firstly, manufacturers of orphan drugs are awarded longer market exclusivity, reduced regulatory fees, tax incentives and line extensions. Secondly, although patient populations for each disease in every market are small, if the drug gains approval across a number of indications, the manufacturer can increase its potential revenue. Thirdly, if successful, manufacturers have the opportunity to be a market leader in a niche area.

Find out more:
www.researchpartnership.com/news/2016/01/pharma-market-research-report-predictions-for-2016/

9th February 2016

Share

Tags

Company Details

Research Partnership

+44 (0)20 8069 5000

Contact Website

Address:
Chester House
Fulham Green
81-83 Fulham High Street
London
SW6 3JW
United Kingdom

Latest content on this profile

Webinar: Portfolio tracking for success
Thursday 18th January 2018 11:00 EST / 16:00 GMT / 17:00 CEST
Research Partnership
20 questions: Round-up video

Research Partnership
Patient centricity: Reality or rhetoric?
Everybody is talking about patient centricity, but what does it mean for those involved in market research, insights and business intelligence?
Research Partnership
Review of Disease Promotion Campaign using Facial Analysis

Research Partnership
Emotional Recognition using Facial Analysis

Research Partnership
Living with NASH: An Unexpected Diagnosis
Published in eyeforpharma November 2017 by Mariel Metcalfe
Research Partnership